东京科学大学发现YAP1–TEAD–TET1表观遗传途径驱动小鼠肝细胞癌
Liver tumors form without detectable driver mutations in mice, revealing epigenetic route
东京科学大学研究团队在《Communications Biology》发表研究,揭示YAP1–TEAD信号轴通过激活TET1介导的DNA去甲基化驱动肝细胞癌发生,且无需 canonical driver gene mutations。在小鼠实验中,抑制TET1可减少肿瘤形成;人类数据同样显示Fontan相关肝病肝细胞中存在该通路高表达。
Cancers can develop through epigenetic pathways even without driver gene mutations (DGMs), according to a study from Science Tokyo. Researchers uncovered the YAP1–TEAD–TET1 axis, which triggers DNA demethylation and activates multiple oncogenes in hepatocellular carcinoma. Suppressing TET1 reduced tumor formation in mice, while analysis of human liver disease data supported the relevance of these findings. This study reveals an alternative epigenetic route to cancer development and offers new insights into DGM-negative cancers.
Most cancers develop from genetic abnormalities that activate proto-oncogenes or inactivate tumor suppressor genes. To identify the changes that drive cancer onset, scientists worldwide use next-generation sequencing, which enables comprehensive analysis of whole genomic and transcriptomic data and aims to uncover driver gene mutations (DGMs).
While DGMs have been identified in the vast majority of cancers, a subset lacks these canonical mutations. The underlying mechanisms that allow these tumors to develop, therefore, remain poorly understood. Understanding how cancer develops without DGMs could reveal alternative routes to tumor formation.
Investigating cancer without driver mutations
In an effort to better understand this mechanism, a research team led by professor Hiroshi Nishina, assistant professor Yoshimi Okamoto-Uchida and doctoral student Misaki Kosaka (at the time of the study), from the Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo (Science Tokyo), Japan, identified an oncogenic mechanism involving DNA demethylation. Their findings, published in the journal Communications Biology, examine how YAP1-TEAD signaling can promote hepatocellular carcinoma (HCC) without canonical DGMs.
This study was conducted in collaboration with professor Teppei Shimamura from the Medical Research Laboratory, Institute of Integrated Research, Science Tokyo; special researcher Haruka Hirose from the National Cancer Center Research Institute, Japan; professor Yutaka Suzuki and special associate professor Akinori Kanai from The University of Tokyo, Japan; professor Akira Suzuki and lecturer Miki Nishio from Kobe University Graduate School of Medicine, Japan; and professor Tomohiko Maehama from Showa Medical University School of Medicine, Japan.
"We hypothesized that a complex composed of the transcriptional coactivator YAP1 and the transcription factor TEAD could promote cancer development not through genomic DNA mutations but by inducing DNA demethylation, and we set out to test this hypothesis," explains Okamoto-Uchida.
TET1 links YAP1 activation to tumors
The researchers created a mosaic mouse model by activating YAP1 in a subset of liver cells via hydrodynamic tail-vein injection. They analyzed the resulting tumors using whole-exome sequencing to identify mutations along with DNA methylation analyses to understand epigenetic changes. The tumors showed no detectable canonical DGMs, while the methylation analyses revealed widespread DNA demethylation associated with the activation of multiple oncogenes. The team then reduced the expression of the Tet1 gene, which encodes ten-eleven translocation (TET1), an enzyme that promotes DNA demethylation, to test its role in tumor development.
The team's approach confirmed that YAP1-TEAD activation enhanced the expression of TET1, thereby promoting DNA demethylation and the activation of multiple cancer-related genes. The findings also showed that suppressing TET1 function reduces tumor formation. Spatial transcriptomic analysis further identified a TET1-high subpopulation of HCC cells interacting with other hepatic cell types. "We observed that the expression of TET1 increased, promoting the activation of multiple cancer-related genes, and that suppressing TET1 function reduced tumor formation," says Okamoto-Uchida.
Human liver disease offers supporting evidence
Furthermore, an analysis of human data revealed elevated YAP1–TEAD–TET1-associated signatures in hepatocytes from patients with Fontan-associated liver disease, a condition associated with HCC and a lower frequency of canonical DGMs. These findings reveal an epigenetic pathway to HCC development that does not depend on canonical DGMs.
Future research could examine whether similar epigenetic pathways operate in other DGM-negative cancers, identify the signals that initiate YAP1-TEAD activation and clarify how TET1 selects its target genes. These questions may help establish whether the pathway offers potential therapeutic targets for further investigation.
Publication details
Misaki Kosaka et al., YAP1 induces hepatocellular carcinoma via DNA demethylation rather than by canonical driver gene mutations, Communications Biology (2026). DOI: 10.1038/s42003-026-10882-w
Journal information: Communications Biology
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Liver tumors form without detectable driver mutations in mice, revealing epigenetic route (2026, October 22) retrieved 22 October 2026 from https://medicalxpress.com/news/2026-10-liver-tumors-driver-mutations-mice.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com